Well Told Grants

Grants / Department of Health and Human Services / National Institutes of Health

Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

Open Closes November 10, 2026 (10 days left) Opportunity RFA-CA-27-001

National Institutes of Health is offering grants of up to $150,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expects to make about 20 awards worth $5.1 million in total. Applications close on November 10, 2026.

From the official notice on Grants.gov, last changed June 3, 2026. Checked October 31, 2026.

Key dates

PostedJune 3, 2026
DeadlineNovember 10, 2026
Archived by Grants.govJanuary 9, 2027

Add the deadline to your calendar

Who can apply

This opportunity is open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility. Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses.

Is this a realistic fit?

What the grant funds

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to develop innovative technologies offering new capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens for basic, clinical, or epidemiological cancer research. The NOFO solicits R61 applications for early-stage projects proposing proof-of-concept/pilot studies to test the technical feasibility of the proposed method, tool, assay, platform, or instrument. Technologies proposed for development may have potential for widespread applicability but must be focused for this program on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Category: Health.

How to apply

  1. Read the full notice and attachments on Grants.gov. The notice is the official source for deadlines and requirements.
  2. Make sure your organization has an active SAM.gov registration and Unique Entity ID; registration can take several weeks.
  3. Register on Grants.gov and submit through Workspace before the deadline and time given in the notice. Our application guide walks through each step.

Questions go to National Institutes of Health, Kelly.crotty@nih.gov, 301-402-2541.

Open the official notice

Questions people ask

Who can apply for Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)?

National Institutes of Health accepts applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

What is the deadline for Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)?

Closes November 10, 2026 (10 days left). Confirm the date and time in the official notice on Grants.gov.

How much funding is available?

Awards of up to $150,000 each. About $5.1 million in total across about 20 awards.

Similar open grants